| scholarly article | Q13442814 |
| P50 | author | Niels Behrendt | Q57167310 |
| P2093 | author name string | U Pessara | |
| A Holm | |||
| K Danø | |||
| G Høyer-Hansen | |||
| U Weidle | |||
| J Pass | |||
| P2860 | cites work | Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis | Q24299135 |
| Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 | Q25938983 | ||
| Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol | Q28646983 | ||
| The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants | Q28647015 | ||
| Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes | Q28647051 | ||
| Urokinase-type plasminogen activator stimulates the Ras/Extracellular signal-regulated kinase (ERK) signaling pathway and MCF-7 cell migration by a mechanism that requires focal adhesion kinase, Src, and Shc. Rapid dissociation of GRB2/Sps-Shc compl | Q30305582 | ||
| A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. | Q33887878 | ||
| A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. | Q33907027 | ||
| Amplification and expression of sequences cotransfected with a modular dihydrofolate reductase complementary DNA gene | Q34253873 | ||
| Localization of the disulfide bonds in the NH2-terminal domain of the cellular receptor for human urokinase-type plasminogen activator. A domain structure belonging to a novel superfamily of glycolipid-anchored membrane proteins | Q34356743 | ||
| Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis | Q34489359 | ||
| The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator | Q34781848 | ||
| An epitope on carcinoembryonic antigen defined by the clinically relevant antibody PR1A3 | Q35227038 | ||
| Transformation of mouse fibroblasts to methotrexate resistance by a recombinant plasmid expressing a prokaryotic dihydrofolate reductase | Q35323487 | ||
| Monoclonal antibody that specifically inhibits a human Mr 52,000 plasminogen-activating enzyme | Q36299757 | ||
| Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction | Q36679850 | ||
| Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes | Q37524689 | ||
| The glycosyl-phosphatidylinositol anchor of membrane proteins | Q38260289 | ||
| Structure-function relationships in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom alpha-neurotoxins | Q40683497 | ||
| A monoclonal antibody against the 66-kDa protein expressed in mouse spleen and thymus inhibits Ly-6A.2-dependent cell-cell adhesion | Q40848643 | ||
| The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria | Q40993621 | ||
| Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect | Q41064411 | ||
| Domain interplay in the urokinase receptor. Requirement for the third domain in high affinity ligand binding and demonstration of ligand contact sites in distinct receptor domains. | Q41168123 | ||
| The urokinase-type plasminogen activator system in cancer metastasis: A review | Q41522331 | ||
| Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain | Q41603641 | ||
| Identification and characterization of the murine cell surface receptor for the urokinase-type plasminogen activator | Q41629036 | ||
| Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor | Q41669188 | ||
| Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer | Q47704430 | ||
| Plasma Urokinase Receptor Levels in Patients With Colorectal Cancer: Relationship to Prognosis | Q63753630 | ||
| A protease-hypersensitive deletion derivative of human tissue-type plasminogen activator | Q67248357 | ||
| A novel method for producing anti-peptide antibodies. Production of site-specific antibodies to the T cell antigen receptor beta-chain | Q68125311 | ||
| Enzyme-linked immunosorbent assay for human urokinase-type plasminogen activator and its proenzyme using a combination of monoclonal and polyclonal antibodies | Q70302473 | ||
| The urokinase receptor is a major vitronectin-binding protein on endothelial cells | Q71034141 | ||
| Identification of the urokinase receptor as an adhesion receptor for vitronectin | Q71663798 | ||
| Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor | Q72089738 | ||
| A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors | Q72721286 | ||
| Quantitation of the receptor for urokinase plasminogen activator by enzyme-linked immunosorbent assay | Q72773587 | ||
| Cell-surface acceleration of urokinase-catalyzed receptor cleavage | Q73067924 | ||
| The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction | Q74121187 | ||
| Differential expression of a truncated form of the urokinase-type plasminogen-activator receptor in normal and tumor thyroid cells | Q74356125 | ||
| Different mechanisms are involved in the antibody mediated inhibition of ligand binding to the urokinase receptor: a study based on biosensor technology | Q74449428 | ||
| Cleavage of the glycosylphosphatidylinositol anchor affects the reactivity of thy-1 with antibodies | Q77404855 | ||
| Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression | Q77966087 | ||
| Src-dependence and pertussis-toxin sensitivity of urokinase receptor-dependent chemotaxis and cytoskeleton reorganization in rat smooth muscle cells | Q77974838 | ||
| P433 | issue | Pt 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 673-679 | |
| P577 | publication date | 2001-09-01 | |
| P1433 | published in | Biochemical Journal | Q864221 |
| P1476 | title | Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor | |
| P478 | volume | 358 |
| Q40105822 | A cleavage-resistant urokinase plasminogen activator receptor exhibits dysregulated cell-surface clearance |
| Q33709060 | Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - β1 (TGF-β1) and potential effects on migration and invasion. |
| Q40428098 | Cross-talk between fMLP and vitronectin receptors triggered by urokinase receptor-derived SRSRY peptide |
| Q40240320 | Dimerization controls the lipid raft partitioning of uPAR/CD87 and regulates its biological functions |
| Q35097486 | Epithelial and stromal cell urokinase plasminogen activator receptor expression differentially correlates with survival in rectal cancer stages B and C patients |
| Q46154986 | High mortality risk among individuals assumed to be TB-negative can be predicted using a simple test |
| Q36158746 | Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients |
| Q37345362 | Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer |
| Q34466969 | Ligand binding alters dimerization and sequestering of urokinase receptors in raft-mimicking lipid mixtures |
| Q36844303 | Models, mechanisms and clinical evidence for cancer dormancy |
| Q57609583 | Plasma Levels of Intact and Cleaved Urokinase Receptor Decrease in HIV-1-Infected Patients Initiating Highly Active Antiretroviral Therapy |
| Q35749341 | Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity |
| Q36549551 | Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models |
| Q35949789 | The Pseudomonas aeruginosa LasB metalloproteinase regulates the human urokinase-type plasminogen activator receptor through domain-specific endoproteolysis |
| Q40701611 | The cleavage of the urokinase receptor regulates its multiple functions |
| Q28257803 | The urokinase receptor (uPAR) and the uPAR-associated protein (uPARAP/Endo180): membrane proteins engaged in matrix turnover during tissue remodeling |
| Q39030266 | The urokinase receptor takes control of cell migration by recruiting integrins and FPR1 on the cell surface |
| Q34089936 | Tumour microenvironments induce expression of urokinase plasminogen activator receptor (uPAR) and concomitant activation of gelatinolytic enzymes |
Search more.